H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating and $30.00 price target on Generate Biomedicines (NASDAQ: GENB).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments